ArticleFrontiers in pharmacology2022
Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Metabolomic profiling reveals distinct and shared biology in COPD and IPF.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- A practical toolbox for modelling fibrosis in vitro.Nature biomedical engineering · 2026Review
- Review
- Hermansky-Pudlak Syndrome Pulmonary Fibrosis: Monogenic Disorder, Multi-Omics Discovery.American journal of respiratory cell and molecular biology · 2026Article
- Identification of diagnostic and prognostic phospholipid biomarkers in idiopathic pulmonary fibrosis via machine learning and in vivo validation.Human genomics · 2025Article
- Altered Metabolism in Idiopathic Pulmonary Fibrosis.Journal of cellular physiology · 2025Review
- Multi-omic analysis identifies biological processes underlying progressive interstitial lung disease in systemic sclerosis.The FEBS journal · 2025Article
- Potential biomarkers of idiopathic pulmonary fibrosis: metabonomics driven lipid profiling.Journal of translational medicine · 2025Article
- Dysregulated metabolic pathways of pulmonary fibrosis and the lipids associated with the effects of nintedanib therapy.Respiratory research · 2025Article
- Integrating Metabolomics and Network Analyses to Explore Mechanisms ofInternational journal of molecular sciences · 2025Article
- A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity.Physiological reports · 2024Article
- Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect ofJournal of pharmaceutical analysis · 2024Article
- Application of Metabolomics across the Spectrum of Pulmonary and Critical Care Medicine.American journal of respiratory cell and molecular biology · 2024Review
- Analysis of clinical characteristics and prognosis of lung cancer patients with CPFE or COPD: a retrospective study.BMC pulmonary medicine · 2024Article
- Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.Respiratory research · 2024Observational
- Review
- Metabolomic Changes in Rat Serum after Chronic Exposure to Glyphosate-Based Herbicide.Metabolites · 2024Article
- Plasma metabolomics and quantitative interstitial abnormalities in ever-smokers.Respiratory research · 2023Article
- Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022.Analytical science advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality and morbidity. Approval of antifibrotic therapy has ameliorated disease progression, but therapy response is heterogeneous and to date, adequate biomarkers predicting therapy response are lacking. In recent years metabolomic technology has improved and is broadly applied in cancer research thus enabling its use in other fields. Recently both aberrant metabolic and lipidomic pathways have been described to influence profibrotic responses. We thus aimed to characterize the metabolomic and lipidomic changes between IPF and healthy volunteers (HV) and analyze metabolomic changes following treatment with nintedanib and pirfenidone. We collected serial serum samples from two IPF cohorts from Germany (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.